These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 27131863)
1. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Fenske TS; Hamadani M; Cohen JB; Costa LJ; Kahl BS; Evens AM; Hamlin PA; Lazarus HM; Petersdorf E; Bredeson C Biol Blood Marrow Transplant; 2016 Sep; 22(9):1543-1551. PubMed ID: 27131863 [TBL] [Abstract][Full Text] [Related]
2. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. Epperla N; Hamadani M Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):277-284. PubMed ID: 28633038 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703 [TBL] [Abstract][Full Text] [Related]
4. Transplantation for non-Hodgkin lymphoma. Nademanee A Expert Rev Hematol; 2009 Aug; 2(4):425-42. PubMed ID: 21082947 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Wirk B; Fenske TS; Hamadani M; Zhang MJ; Hu ZH; Akpek G; Aljurf MD; Armand P; Ayala E; Bachanova V; Bolwell B; Cairo MS; Cashen A; Chen YB; Costa LJ; Farhan S; Freytes CO; Gajewski JL; Gibson J; Hale GA; Holmberg LA; Hsu JW; Inwards DJ; Kamble RT; Maharaj D; Maziarz RT; Munker R; Nath R; Reddy NM; Reeder CB; Rizzieri DA; Sauter CS; Savani BN; Schouten HC; Sureda A; Vose JM; Waller EK; Wiernik PH; Gale RP; Burns LJ; Saber W Biol Blood Marrow Transplant; 2014 Jul; 20(7):951-9. PubMed ID: 24641828 [TBL] [Abstract][Full Text] [Related]
6. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? Hamadani M Bone Marrow Transplant; 2013 Aug; 48(8):1013-21. PubMed ID: 23000653 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma. Heinzelmann F; Bethge W; Beelen DW; Stelljes M; Dreger P; Engelhard M; Finke J; Kröger N; Holler E; Bornhäuser M; Müller A; Haubitz I; Ottinger H J Cancer Res Clin Oncol; 2018 Jun; 144(6):1173-1183. PubMed ID: 29623467 [TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma. Bhatt VR; Vose JM Hematol Oncol Clin North Am; 2014 Dec; 28(6):1073-95. PubMed ID: 25459180 [TBL] [Abstract][Full Text] [Related]
9. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients. Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. Rezvani AR; Kanate AS; Efron B; Chhabra S; Kohrt HE; Shizuru JA; Laport GG; Miklos DB; Benjamin JE; Johnston LJ; Arai S; Weng WK; Negrin RS; Strober S; Lowsky R Bone Marrow Transplant; 2015 Oct; 50(10):1286-92. PubMed ID: 26146806 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369 [TBL] [Abstract][Full Text] [Related]
12. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459 [TBL] [Abstract][Full Text] [Related]
13. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. Crocchiolo R; Castagna L; Fürst S; El-Cheikh J; Faucher C; Oudin C; Granata A; Bouabdallah R; Coso D; Chabannon C; Balzarotti M; Santoro A; Blaise D Bone Marrow Transplant; 2013 Feb; 48(2):249-52. PubMed ID: 22732704 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Shah NN; Ahn KW; Litovich C; Fenske TS; Ahmed S; Battiwalla M; Bejanyan N; Dahi PB; Bolaños-Meade J; Chen AI; Ciurea SO; Bachanova V; DeFilipp Z; Epperla N; Farhadfar N; Herrera AF; Haverkos BM; Holmberg L; Hossain NM; Kharfan-Dabaja MA; Kenkre VP; Lazarus HM; Murthy HS; Nishihori T; Rezvani AR; D'Souza A; Savani BN; Ulrickson ML; Waller EK; Sureda A; Smith SM; Hamadani M Blood Adv; 2018 Apr; 2(8):933-940. PubMed ID: 29685953 [TBL] [Abstract][Full Text] [Related]
15. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma. Tada K; Kim SW; Asakura Y; Hiramoto N; Yakushijin K; Kurosawa S; Tajima K; Mori S; Heike Y; Tanosaki R; Maeshima AM; Taniguchi H; Furuta K; Kagami Y; Matsuno Y; Tobinai K; Takaue Y; Fukuda T Am J Hematol; 2012 Aug; 87(8):770-5. PubMed ID: 22641292 [TBL] [Abstract][Full Text] [Related]